Faecal tests are widely applied for colorectal cancer (CRC) screening and considered for triaging symptomatic patients with suspected CRC. However, faecal tests can be inconvenient, complex and expensive. Colorectal mucus (CM) sampled using our new patient-friendly non-invasive technique is rich in CRC biomarkers. This study aimed to evaluate diagnostic accuracy of CRC detection by measuring protein biomarkers in CM.
Colorectal mucus samples were provided by 35 healthy controls, 62 CRC-free symptomatic patients and 40 CRC patients. Biomarkers were quantified by ELISA. Diagnostic performances of haemoglobin, C-reactive protein, tissue inhibitor of metalloproteinases-1, M2-pyruvate kinase, matrix metalloproteinase-9, peptidyl arginine deiminase-4, epidermal growth factor receptor, calprotectin and eosinophil-derived neurotoxin were assessed using receiver operating characteristic (ROC) curve analysis.
Colorectal mucus haemoglobin was superior compared to other biomarkers. For haemoglobin, the areas under the curve for discriminating between CRC and healthy groups (‘screening’) and between CRC and symptomatic patients (‘triage’) were 0.921 and 0.854 respectively. The sensitivity of 80.0% and specificities of 94.3% and 85.5% for the two settings respectively were obtained.
Haemoglobin quantification in CM reliably detects CRC. This patient-friendly approach presents an attractive alternative to faecal immunochemical test; however, the two methods need to be directly compared in larger studies.
Subscribe to Journal
Get full journal access for 1 year
only $32.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019).
Young, G. P., Rabeneck, L. & Winawer, S. J. The global paradigm shift in screening for colorectal cancer. Gastroenterology 156, 843–851 (2019).
Grady, W. M. & Markowitz, S. D. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig. Dis. Sci. 60, 762–772 (2015).
Brenner, H. & Chen, C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. Br. J. Cancer 119, 785–792 (2018).
Dekker, E. & Rex, D. K. Advances in CRC prevention: screening and surveillance. Gastroenterology 154, 1970–1984 (2018).
Brenner, H. & Tao, S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur. J. Cancer 49, 3049–3054 (2013).
Gies, A., Bhardwaj, M., Stock, C., Schrotz-King, P. & Brenner, H. Quantitative fecal immunochemical tests for colorectal cancer screening. Int. J. Cancer 143, 234–244 (2018).
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P. et al. Multitarget stool DNA testing for colorectal cancer screening. N. Engl. J. Med. 370, 1287–1297 (2014).
Ahlquist, D. A., Zou, H., Domanico, M., Mahoney, D. W., Yab, T. C., Taylor, W. R. et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142, 248–256 (2012).
Lidgard, G. P., Domanico, M. J., Bruinsma, J. J., Light, J., Gagrat, Z. D., Oldham-Haltom, R. L. et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin. Gastroenterol. Hepatol. 11, 1313–1318 (2013).
Lansdorp-Vogelaar, I., Goede, S. L., Bosch, L. J. W., Melotte, V., Carvalho, B., van Engeland, M. et al. Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening. Clin. Gastroenterol. Hepatol. 16, 504–512 (2018).
Loktionov, A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J. Gastrointest. Oncol. 12, 124–148 (2020).
Westwood, M., Corro Ramos, I., Lang, S., Luyendijk, M., Zaim, R., Stirk, L. et al. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 21, 1–234 (2017).
White, A., Ironmonger, L., Steele, R. C., Ormiston-Smith, N., Crawford, C. & Seims, A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer 18, 906 (2018).
Lawler, M., Alsina, D., Adams, R. A., Anderson, A. S., Brown, G., Fearhead, N. S. et al. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut 67, 179–193 (2018).
Godber, I. M., Benton, S. C. & Fraser, C. G. Setting up a service for faecal immunochemical test for haemoglobin (FIT): a review of considerations, challenges and constraints. J. Clin. Pathol. 71, 1041–1045 (2018).
Moss, S., Mathews, C., Day, T. J., Smith, S., Seaman, H. E., Snowball, J. et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut 66, 1631–1644 (2017).
Palmer, C. K., Thomas, M. C., von Wagner, C. & Raine, R. Reasons for non-uptake and subsequent participation in the NHS Bowel Cancer Screening Programme: a qualitative study. Br. J. Cancer 110, 1705–1711 (2014).
Reynolds, L. M., Bissett, I. P. & Consedine, N. S. Emotional predictors of bowel screening: the avoidance-promoting role of fear, embarrassment, and disgust. BMC Cancer 18, 518 (2018).
Klabunde, C., Blom, J., Bulliard, J. L., Garcia, M., Hagoel, L., Mai, V. et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. J. Med. Screen 22, 119–126 (2015).
Lo, S. H., Halloran, S., Snowball, J., Seaman, H., Wardle, J. & von Wagner, C. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut 64, 282–291 (2015).
Hirst, Y., Stoffel, S., Baio, G., McGregor, L. & von Wagner, C. Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out. Eur. J. Cancer 103, 267–273 (2018).
Ahlquist, D. A. Molecular detection of colorectal neoplasia. Gastroenterology 138, 2127–2139 (2010).
Loktionov, A. Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int. J. Cancer 120, 2281–2289 (2007).
Pelaseyed, T., Bergström, J. H., Gustafsson, J. K., Ermund, A., Birchenough, G. M., Schütte, A. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 260, 8–20 (2014).
Loktionov, A., Bandaletova, T., Llewelyn, A. H., Dion, C., Lywood, H. G. C., Lywood, R. C. G. et al. Colorectal cancer detection by measuring DNA from exfoliated colonocytes obtained by direct contact with rectal mucosa. Int. J. Oncol. 34, 301–312 (2009).
Loktionov, A., Chhaya, V., Bandaletova, T. & Poullis, A. Assessment of cytology and mucin 2 in colorectal mucus collected from patients with inflammatory bowel disease: results of a pilot trial. J. Gastroenterol. Hepatol. 31, 326–333 (2016).
Bandaletova, T., Chhaya, V., Poullis, A. & Loktionov, A. Colorectal mucus non-invasively collected from patients with inflammatory bowel disease and its suitability for diagnostic cytology. APMIS 124, 160–168 (2016).
Loktionov, A., Chhaya, V., Bandaletova, T. & Poullis, A. Inflammatory bowel disease detection and monitoring by measuring biomarkers in non-invasively collected colorectal mucus. J. Gastroenterol. Hepatol. 32, 992–1002 (2017).
Loktionov, A., Soubieres, A., Bandaletova, T., Mathur, J. & Poullis, A. Colorectal cancer detection by biomarker quantification in noninvasively collected colorectal mucus: preliminary comparison of 24 protein biomarkers. Eur. J. Gastroenterol. Hepatol. 31, 1220–1227 (2019).
Hajian-Tilaki, K. Sample size estimation in diagnostic test studies of biomedical informatics. J. Biomed. Inf. 48, 193–204 (2014).
Bossuit, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351, h5527 (2015).
Cohen, J. F., Korevaar, D. A., Altman, D. G., Bruns, D. E., Gatsonis, C. A., Hooft, L. et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 6, e012799 (2016).
Unal, I. Defining an optimal Cut-point value in ROC analysis: an alternative approach. Comput. Math. Methods Med. 2017, 3762651 (2017).
Menees, S. B., Powell, C., Kurlander, J., Goel, A. & Chey, W. D. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol. 110, 444–454 (2015).
Goyal, A., Terry, M. B., Jin, Z. & Siegel, A. B. C-reactive protein and colorectal cancer mortality in U.S. adults. Cancer Epidemiol. Biomark. Prev. 23, 1609–1618 (2014).
Holten-Andersen, M. N., Hansen, U., Brünner, N., Nielsen, H. J., Illemann, M. & Nielsen, B. S. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int. J. Cancer 113, 198–206 (2005).
Illemann, M., Eefsen, R. H., Bird, N. C., Majeed, A., Osterlind, K., Laerum, O. D. et al. Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures. Mol. Carcinog. 55, 193–208 (2016).
Lorenc, Z., Waniczek, D., Lorenc-Podgórska, K., Krawczyk, W., Domagała, M., Majewski, M. et al. Profile of expression of genes encoding matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 28 (MMP28) and TIMP metalloproteinase inhibitor 1 (TIMP1) in colorectal cancer: assessment of the role in diagnosis and prognostication. Med. Sci. Monit. 23, 1305–1311 (2017).
Christensen, I. J., Brünner, N., Dowell, B., Davis, G., Nielsen, H. J., Newstead, G. et al. Plasma TIMP-1 and CEA as markers for detection of primary colorectal cancer: a prospective validation study including symptomatic and non-symptomatic individuals. Anticancer Res. 35, 4935–4941 (2015).
Wilhelmsen, M., Christensen, I. J., Rasmussen, L., Jørgensen, L. N., Madsen, M. R., Vilandt, J. et al. Detection of colorectal neoplasia: combination of eight blood-based, cancer-associated protein biomarkers. Int. J. Cancer 140, 1436–1446 (2017).
Meng, C., Yin, X., Liu, J., Tang, K. & Liao, J. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: a meta-analysis. PLoS ONE 13, e0207039 (2018).
Karl, J., Wild, N., Tacke, M., Andres, H., Garczarek, U., Rollinger, W. et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol. 6, 1122–1128 (2008).
Annaházi, A., Ábrahám, S., Farkas, K., Rosztóczy, A., Inczefi, O., Földesi, I. et al. A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer. Br. J. Cancer 114, 787–792 (2016).
Haug, U., Hundt, S. & Brenner, H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br. J. Cancer 99, 133–135 (2008).
Leen, R., Seng-Lee, C., Holleran, G., O’Morain, C. & McNamara, D. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort. Eur. J. Gastroenterol. Hepatol. 26, 514–518 (2014).
Masuda, S., Nakazawa, D., Shida, H., Miyoshi, A., Kusunoki, Y., Tomaru, U. et al. NETosis markers: quest for specific, objective, and quantitative markers. Clin. Chim. Acta 459, 89–93 (2016).
Brinkmann, V. Neutrophil extracellular traps in the second decade. J. Innate Immun. 10, 414–421 (2018).
Richardson, J. J. R., Hendrickse, C., Gao-Smith, F. & Thickett, D. R. Neutrophil extracellular trap production in patients with colorectal cancer in vitro.Int. J. Inflamm. 2017, 4915062 (2017).
The authors would like to thank all patients and healthy volunteers for their participation in the study. We are also grateful to Linda Howard, Lucy Pippard, Lesley Nichols and Juliah Jonasi for their excellent assistance in recruiting study participants.
Ethics approval and consent to participate
The protocol of the study was approved by London-South East Research Ethics Committee (16/LO/2273) in accordance with the Declaration of Helsinki. All recruited patients and healthy volunteers provided written informed consent.
All data generated by the study are included in the article.
A.L. and T.B. are founders and directors of DiagNodus Ltd. For the remaining authors, there are no conflicts of interest.
This study was supported by a grant (ref. 132672) from Innovate UK (UK Technology Strategy Board) to DiagNodus Ltd. Apart from grant provision the funding source was not involved in any aspect of the study.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Loktionov, A., Soubieres, A., Bandaletova, T. et al. Biomarker measurement in non-invasively sampled colorectal mucus as a novel approach to colorectal cancer detection: screening and triage implications. Br J Cancer 123, 252–260 (2020). https://doi.org/10.1038/s41416-020-0893-8